TP-102

AXP000224.1 · Phage therapy

Platform
phage cocktail (non-engineered)
Originator
Technophage
Sponsor
Technophage

Names

NameTypeSource
TP-102preferred name, codecurator, ctgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
bacteriophage cocktail against P. aeruginosa, S. aureus and A. baumannii
Replication
replicating
Route
topical
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05948592Bacteriophage Therapy TP-102 in Patients With Diabetic Foot InfectionCompletedPhase 22023-11-082025-10-3076Diabetic Foot Infection
NCT04803708Bacteriophage Therapy TP-102 in Diabetic Foot UlcersCompletedPhase 1/22021-03-222022-08-0720Acinetobacter Infection; Diabetic Foot Ulcer; Pseudomonas Aeruginosa Infection; Staphylococcus Aureus Infection

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39740667Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers.Med (New York, N.Y.)2025cited by trial NCT04803708

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41305207Enhancing Intersection Efficiency: A Comparative Analysis of Converting Single-Lane Roundabout to Turbo Roundabout.Sensors (Basel, Switzerland)2025name in abstract: TP-102

Notes

Topical phage cocktail for diabetic foot ulcers and infection, covering Pseudomonas aeruginosa, Staphylococcus aureus and Acinetobacter baumannii. Phase 1/2a NCT04803708 (published) and phase 2 NCT05948592, both completed.

How to cite

TP-102 (AXP000224.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000224.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.